Primary testicular lymphoma: A strictly homogeneous hematological disease?

Oncology Reports

Volumn 23, Issue 5, 2010, Pages 1261-1267

  Kemmerling, Ralf ^a   Stintzing, Sebastian ^c   Mühlmann, Josef ^b   Dietze, Otto ^a   Neureiter, Daniel ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Subclassification; Survival; Testicular lymphoma

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; TUMOR ANTIGEN; VINCRISTINE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; GERIATRIC PATIENT; GERMINAL CENTER; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; ORCHIECTOMY; OVERALL SURVIVAL; PHENOTYPE; PRIMARY TESTICULAR LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CHI-SQUARE DISTRIBUTION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TESTICULAR NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77950819862     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000759     Document Type: Article

References (27)

1. Vitolo U, Ferreri AJ and Zucca E: Primary testicular lymphoma. Crit Rev Oncol Hematol 65: 183-189, 2008.
2. Al Abbadi MA, Hattab EM, Tarawneh MS, Amr SS, Orazi A and Ulbright TM: Primary testicular diffuse large B-cell lymphoma belongs to the non-germinal center B-cell-like subgroup: a study of 18 cases. Mod Pathol 19: 1521-1527, 2006.
3. Hasselblom S, Ridell B, Wedel H, Norrby K, Sender BM and Ekman T: Testicular lymphoma - a retrospective, populationbased, clinical and immunohistochemical study. Acta Oncol 43: 758-765, 2004.
4. Booman M, Douwes J, Glas AM, de Jong D, Schuuring E and Kluin PM: Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics. J Pathol 210: 163-171, 2006.
5. Ferry JA, Harris NL, Young RH, Coen J, Zietman A and Scully RE: Malignant lymphoma of the testis, epididymis, and spermatic cord. A clinicopathologic study of 69 cases with immunophenotypic analysis. Am J Surg Pathol 18: 376-390, 1994.
6. Tondini C, Ferreri AJ, Siracusano L, Valagussa P, Giardini R, Rampinelli I and Bonadonna G: Diffuse large-cell lymphoma of the testis. J Clin Oncol 17: 2854-2858, 1999.
7. Vural F, Cagirgan S, Saydam G, Hekimgil M, Soyer NA and Tombuloglu M: Primary testicular lymphoma. J Natl Med Assoc 99: 1277-1282, 2007.
8. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO and Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000.
9. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO and Chan WC: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282, 2004.
10. Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, Morgan GJ and Jack AS: Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99: 1136-1143, 2002.
11. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T and Staudt LM: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937- 1947, 2002.
12. Connor J and Ashton-Key M: Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study. Histopathology 51: 697-703, 2007.
13. Fisher RI, Miller TP and O'Connor OA: Diffuse aggressive lymphoma. Hematology. Am Soc Hematol Educ Program, 221-236, 2004.
14. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329: 987-994, 1993.
15. Quint K, Stintzing S, Alinger B, Hauser-Kronberger C, Dietze O, Gahr S, Hahn EG, Ocker M and Neureiter D: The expression pattern of PDX-1, SHH, patched and gli-1 is associated with pathological and clinical features in human pancreatic cancer. Pancreatology 9: 116-126, 2008.
16. Pasqualucci L, Guglielmino R, Houldsworth J, Mohr J, Aoufouchi S, Polakiewicz R, Chaganti RS and Dalla-Favera R: Expression of the AID protein in normal and neoplastic B cells. Blood 104: 3318-3325, 2004.
17. Buzelin F, Karam G, Moreau A, Wetzel O and Gaillard F: Testicular tumor and the acquired immunodeficiency syndrome. Eur Urol 26: 71-76, 1994.
18. Sokovich RS, Bormes TP and McKiel CF: Acquired immunodeficiency syndrome presenting as testicular lymphoma. J Urol 147: 1110-1111, 1992.
19. Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, Kajdacsy-Balla A and Perkins SL: Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 28: 464-470, 2004.
20. Smit LA, Bende RJ, Aten J, Guikema JE, Aarts WM and van Noesel CJ: Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinalcenter phenotype. Cancer Res 63: 3894-3898, 2003.
21. Hardianti MS, Tatsumi E, Syampurnawati M, Furuta K, Saigo K, Nakamachi Y, Kumagai S, Ohno H, Tanabe S, Uchida M and Yasuda N: Activation-induced cytidine deaminase expression in follicular lymphoma: association between AID expression and ongoing mutation in FL. Leukemia 18: 826-831, 2004.
22. Specht K, Kremer M, Muller U, Dirnhofer S, Rosemann M, Hofler H, Quintanilla-Martinez L and Fend F: Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections. Clin Cancer Res 8: 2902-2911, 2002.
23. Booman M, Douwes J, Glas AM, Riemersma SA, Jordanova ES, Kok K, Rosenwald A, De Jong D, Schuuring E and Kluin PM: Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma. Clin Cancer Res 12: 2698-2705, 2006.
24. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC and Connors JM: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90: 244-251, 1997. (Pubitemid 27276568)
25. De Leval L and Harris NL: Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 43: 509-528, 2003.
26. Sanchez E, Chacon I, Plaza MM, Munoz E, Cruz MA, Martinez B, Lopez L, Martinez-Montero JC, Orradre JL, Saez AI, Garcia JF and Piris MA: Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 16: 1931-1939, 1998.
27. Booman M, Szuhai K, Rosenwald A, Hartmann E, Kluin- Nelemans H, de Jong D, Schuuring E and Kluin P: Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol 216: 209- 217, 2008.